tiprankstipranks
Trending News
More News >
Scorpius Holdings (SCPX)
OTHER OTC:SCPX
Advertisement

Scorpius Holdings (SCPX) AI Stock Analysis

Compare
2,656 Followers

Top Page

SCPX

Scorpius Holdings

(OTC:SCPX)

Rating:38Underperform
Price Target:
$0.00
▼(-100.00%Downside)
Scorpius Holdings' overall stock score is heavily impacted by its poor financial performance, with persistent losses and high leverage posing significant risks. Technical analysis suggests a bearish trend, and valuation metrics highlight profitability challenges. The recent delisting and board member resignation further undermine investor confidence.

Scorpius Holdings (SCPX) vs. SPDR S&P 500 ETF (SPY)

Scorpius Holdings Business Overview & Revenue Model

Company DescriptionScorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
How the Company Makes MoneyScorpius Holdings generates revenue primarily through its ownership stakes in the businesses it acquires. This includes earning dividends from profitable subsidiaries, capital gains from the appreciation of its investments, and management fees charged for overseeing operations and strategic direction. Additionally, SCPX may engage in joint ventures and strategic partnerships that provide additional revenue streams, as well as potential profit-sharing arrangements with invested companies. The company's ability to identify and integrate high-growth opportunities is a critical factor in its financial success.

Scorpius Holdings Financial Statement Overview

Summary
Scorpius Holdings faces significant financial hurdles across all major financial statements. The company struggles with revenue growth and profitability, as evidenced by negative margins and net income. Its financial structure is burdened by high debt levels, and cash flows are deeply negative, threatening liquidity and operational sustainability. These factors collectively underscore the need for strategic financial turnaround to stabilize and improve financial health.
Income Statement
15
Very Negative
Scorpius Holdings exhibits significant financial challenges with persistent negative net income and EBIT across multiple years. The company shows declining revenue growth, with a marked revenue drop from the previous year. Gross profit margins are negative, indicating cost management issues. Overall, the income statement reflects operational inefficiencies and a struggle to achieve profitability.
Balance Sheet
25
Negative
The balance sheet reveals a high debt-to-equity ratio, indicating reliance on debt financing, which can pose financial risk. The equity ratio is low, reflecting limited shareholder investment relative to total assets. The company's return on equity is negative due to consecutive net losses, highlighting poor performance in generating shareholder returns. These factors signal financial instability and potential solvency risks.
Cash Flow
10
Very Negative
The cash flow statement presents a concerning picture with negative operating and free cash flows, suggesting the company struggles to generate cash from its operations. The free cash flow to net income ratio is unfavorable, posing liquidity challenges. Overall, the cash flow metrics indicate a dire need for improved cash management and operational efficiency.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.24M6.99M5.98M2.11M2.95M
Gross Profit3.05M-2.22M-420.02K1.42M2.95M
EBITDA-26.22M-33.99M-39.29M-34.86M-24.59M
Net Income-32.81M-45.22M-43.43M-35.07M-26.05M
Balance Sheet
Total Assets39.18M51.04M104.40M120.96M124.19M
Cash, Cash Equivalents and Short-Term Investments1.16M2.39M44.27M96.38M111.77M
Total Debt28.55M14.04M9.39M1.93M1.85M
Total Liabilities37.50M22.74M31.96M8.93M8.70M
Stockholders Equity6.30M31.40M73.92M113.11M116.24M
Cash Flow
Free Cash Flow-26.88M-33.52M-25.82M-40.03M-22.36M
Operating Cash Flow-26.01M-31.53M-5.70M-38.13M-22.02M
Investing Cash Flow1.21M32.24M10.99M9.77M-95.42M
Financing Cash Flow25.64M-8.95M-4.91M25.49M119.33M

Scorpius Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.05
Negative
100DMA
0.08
Negative
200DMA
0.28
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
31.14
Neutral
STOCH
18.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.05, and below the 200-day MA of 0.28, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 31.14 is Neutral, neither overbought nor oversold. The STOCH value of 18.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCPX.

Scorpius Holdings Risk Analysis

Scorpius Holdings disclosed 48 risk factors in its most recent earnings report. Scorpius Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Scorpius Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.64B0.15-63.05%2.08%16.20%0.83%
45
Neutral
$4.97M-468.00%98.55%
38
Underperform
$136.26K-174.06%-10.75%82.25%
33
Underperform
$2.17M-237.69%-97.16%
30
Underperform
$1.60M-300.16%79.57%
29
Underperform
$6.36M-192.72%56.26%
15
Underperform
$1.44M-431.29%48.17%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SCPX
Scorpius Holdings
0.01
-2.29
-99.57%
SLRX
Salarius Pharmaceuticals
0.75
-2.98
-79.89%
PCSA
Processa Pharmaceuticals
0.24
-1.46
-85.88%
VINC
Vincerx Pharma Inc
0.28
-12.72
-97.85%
GRI
GRI Bio
1.99
-11.89
-85.66%
ONCO
Onconetix
4.15
-597.65
-99.31%

Scorpius Holdings Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Scorpius Holdings Amends Convertible Note Agreement
Neutral
Jul 23, 2025

On July 11, 2025, Scorpius Holdings, Inc. amended its 9% senior secured convertible note with an institutional investor, adjusting the conversion price and removing provisions related to stockholder approval for share conversion. This amendment impacts the company’s ability to convert the note into shares of common stock, potentially issuing a significant number of shares if fully converted. Additionally, the company issued a non-convertible promissory note worth $485,000, which accrues interest at 5% per annum and includes provisions for redemption upon certain events.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Private Placements and Financing
Scorpius Holdings Issues $425,000 Promissory Note
Neutral
Jul 3, 2025

On June 30, 2025, Scorpius Holdings, Inc. issued a non-convertible promissory note valued at $425,000 to an institutional investor, with an interest rate of 5% per annum. The note, which matures on August 31, 2025, or upon a corporate event or default, includes a 5% premium payment upon maturity, redemption, or prepayment. The note allows the holder to demand redemption using proceeds from any subsequent financing by the company.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Scorpius Holdings Issues $130,000 Promissory Note
Neutral
Jun 23, 2025

On June 18, 2025, Scorpius Holdings, Inc. issued a non-convertible promissory note worth $130,000 to an institutional investor. The note, which accrues interest at 5% per annum, is set to mature by July 31, 2025, or upon the occurrence of a corporate event or default. The issuance was made under an exemption from registration requirements, allowing the company to secure funds without a public offering, potentially impacting its financial strategy and stakeholder interests.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Executive/Board Changes
Scorpius Holdings Board Member Tan Sze Thuan Resigns
Neutral
Jun 5, 2025

On June 4, 2025, Tan Sze Thuan resigned from his position as a member of the Board of Directors at Scorpius Holdings, Inc., effective immediately. His departure was not due to any disagreements with the company’s operations, policies, or practices, and he did not serve on any board committees.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Private Placements and Financing
Scorpius Holdings Issues $535,000 Promissory Note
Neutral
Jun 3, 2025

On May 30, 2025, Scorpius Holdings, Inc. issued a non-convertible promissory note worth $535,000 to an institutional investor, with an interest rate of 5% per annum and a maturity date of July 31, 2025, or upon a corporate event or default. The note includes standard default events, and the holder can demand redemption if the company secures subsequent financing. The note was sold under an exemption from registration as per the Securities Act of 1933.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Private Placements and Financing
Scorpius Holdings Issues Promissory Note to Investor
Neutral
May 20, 2025

On May 15, 2025, Scorpius Holdings, Inc. issued a non-convertible promissory note valued at $450,000 to an institutional investor. The note, which accrues interest at 5% per annum, is set to mature by July 31, 2025, or upon a corporate event or default. The issuance was exempt from registration under the Securities Act of 1933. CEO Jeff Wolf provided a personal guaranty for the note, ensuring payment obligations are met by December 31, 2028, which could impact the company’s financial commitments and stakeholder confidence.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Private Placements and Financing
Scorpius Holdings Completes Major Private Placement Offering
Neutral
May 14, 2025

Scorpius Holdings, Inc., a Delaware corporation, recently completed a private placement offering in May 2025, resulting in the issuance of 48,755,000 shares of its common stock. This brings the total number of outstanding shares to 61,142,712, potentially impacting the company’s market positioning and shareholder value.

The most recent analyst rating on (SCPX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Scorpius Holdings stock, see the SCPX Stock Forecast page.

Delistings and Listing ChangesExecutive/Board Changes
Scorpius Holdings Director Resignation Announced
Negative
May 2, 2025

On April 21, 2025, Scorpius Holdings, Inc., a Delaware-based company, received a notice from NYSE Regulation about the suspension of its common stock trading due to low selling prices, leading to its delisting from the NYSE American. The company did not appeal this decision, and its stock began trading on the OTC Market on April 22, 2025. Additionally, on May 2, 2025, John Prendergast, a member of the Board of Directors, resigned without any noted disagreements with the company’s operations or policies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 28, 2025